Alternate-Day Micafungin Antifungal Prophylaxis in Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation: A Pharmacokinetic Study  by Mehta, Parinda A. et al.
BRIEF ARTICLESFrom the
Defic
colog
Cente
Financial d
Correspon
sion o
Cance
Hosp
parind
Received A
 2010 Am
1083-8791
doi:10.101
1458Alternate-Day Micafungin Antifungal Prophylaxis in
Pediatric Patients Undergoing Hematopoietic Stem
Cell Transplantation: A Pharmacokinetic Study
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Michael B. Jordan,1 Rebecca Marsh,1 Richard Tarin,1 Stephanie Edwards,1 Deborah Fearing,1
Julia Lawrence,1 Stella M. Davies1Disseminated fungal infection is a major cause of morbidity and mortality in children undergoing hematopoi-
etic stem cell transplantation (HSCT). Prophylaxis with amphotericin B can be limited by renal toxicity. Oral
triazoles can be limited by poor absorption, large interindividual pharmacokinetic (PK) variability, and hepatic
toxicity, leading to interruptions in therapy and breakthrough infections. Intravenous (i.v.) micafungin has po-
tential advantages, because of its better safety profile, specifically in terms of hepatic and renal toxicity, and
lack of drug-drug interactions with common medications used in the HSCT setting. We hypothesized that
higher dose micafungin (3 mg/kg) every other day will provide drug exposure similar to standard dosing
(1 mg/kg) given daily, and improve patient compliance in very young children in whom oral medications
can be challenging, at reduced administration costs. Both animal and adult patient data support the use of
this approach. Fifteen children (M/F 5 11/4, aged #10 years; mean: 3.9 years, range: 0.6-10 years) with var-
ious hematologic, metabolic, and immune deficiency disorders undergoing HSCT received a single dose of
micafungin (3 mg/kg) i.v. over 1 hour. Dose selection was based on published PK data in pediatric patients,
and exploration of different dosing regimens using Monte Carlo PK/PD simulation. Blood samples were
drawn around this dose and PK analysis was conducted using standard noncompartmental methods. Mica-
fungin at 3 mg/kg dose was well tolerated in all patients. Measurable plasma concentrations were present
in all cases at 48 hours. Half-life and clearance observed were comparable to previous pediatric PK data,
with clearance being higher than adults as expected. Volume of distribution was higher in our patients com-
pared to published pediatric data, likely because of a larger proportion of very young children in our study
cohort. After correction for protein binding, concentrations at the end of the dosing interval during main-
tenance treatment remain above the minimum inhibitory concentration (MIC) of highly susceptible fungal
pathogens. These data suggest that alternate day micafungin dosing, as described here, may provide an attrac-
tive alternative for antifungal prophylaxis in HSCT patients and merits further evaluation.
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6/j.bbmt.2010.05.002children. Children with leukemias (eg, acute myeloge-
nous leukemia [AML], relapsed acute lymphoblastic
leukemia [ALL]), bone marrow failure syndromes, or
immune deficiencies, and those undergoing allogeneic
hematopoietic stem cell transplantation (HSCT) are at
highest risk [1-3]. Graft-versus-host disease (GVHD)
after allogeneic HSCT requires further immunosup-
pression, and in turn, increases the risk of invasive fun-
gal infections. The leading causes of opportunistic
fungal infections in these patients are Candida and
Aspergillus species [1,4].
The life-threatening nature of invasive fungal in-
fections warrants prophylaxis. A number of options
are available for prophylaxis, but none have been found
to be ideal. Oral triazoles are limited by poor absorp-
tion of some products, interindividual variation in
metabolism, and hepatic toxicity, leading to reports
Table 1. Patient Demographics
Patient No. Age (Years) Gender Weight (kg) Diagnosis
1 0.6 M 8.45 WAS
2 0.7 M 7.7 Marrow failure
3 1.6 M 10.4 WAS
4 2.0 M 12.7 WAS
5 2.4 M 14.9 WAS
6 2.5 M 13.8 NBL
7 2.6 M 10.5 FA
8 3.4 F 16.2 JMML
9 3.7 M 16.5 AML
10 4.0 M 15.9 WAS
11 4.8 F 26.5 FA
12 4.9 M 21 AA
13 6.3 F 18 FA
14 8.9 M 30.3 Ewing’s sarcoma
15 10.4 F 32.1 FA
JMML indicates juvenile myelomomocytic leukemia; FA, Fanconi anemia;
AML, acute myelogenous leukemia; NBL, neuroblastoma; WAS,
Wiskott-Aldrich syndrome.
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photericin B has been shown to reduce the frequency
of invasive fungal infections in some populations [6].
but widespread and long-term use is limited because
of associated infusional toxicity and long-term nephro-
toxic side effects [7].
An alternative approach to prophylaxis is the use of
every other day intravenous (i.v.) micafungin. Mica-
fungin is an i.v. antifungal compound of the echino-
candin class. Micafungin acts by inhibiting the
production of 1,3-b-D-glucan, a key component in
fungal cell wall synthesis [8]. A semisynthetic lipopep-
tide, micafungin possesses in vitro and in vivo activity
against a broad spectrum of Candida and Aspergillus
species, including activity against azole-resistant Can-
dida [9-13]. The safety and plasma pharmacokinetics
(PK) of micafungin have been well studied in animal
models [12,14] and in adult patients [15]. Althoughmi-
cafungin has the most pediatric data of the 3 echino-
candins, data are still limited about the properties of
this echinocandin in pediatric patients. This is in large
part because of the fact that most of the pediatric stud-
ies have been performed in neonates and very low birth
weight babies [15-18].
There are a number of potential advantages in the
use of alternate day micafungin for fungal prophylaxis.
This strategy is simple and convenient for patients,
with little infusional toxicity and compliance is assured
in young children in whom frequent oral medication
can be a challenge. Alternate day dosing is less burden-
some than the customary daily i.v. dosing for home
therapy if prolonged prophylaxis after initial hospital-
ization is required. Micafungin has a more favorable
safety profile compared with azoles and amphotericin
B with low frequencies of hepatic and renal toxicity
[19]. In addition, micafungin does not have drug
interactions with tacrolimus, prednisone, cyclospor-
ine, or mycophenolate mofetil, some of the common
medications used in the HSCT setting [20].
Currently, children who receive micafungin are
given daily dosing. To investigate the potential of al-
ternate day prophylactic administration, we performed
a PK study of micafungin (higher dose, 3 mg/kg every
other day instead of standard dose, 1 mg/kg given
daily) in young children undergoing HSCT.METHODS
This study is a prospective opened-label single
center observational clinical trial to establish the PK
of alternate day micafungin therapy in young children.
Patients receiving HSCT in whom antifungal prophy-
laxis was clinically indicated were eligible for the study.
A total of 15 children with various hematologic disor-
ders, metabolic disorders, and immune deficiency syn-
dromes undergoing HSCT were enrolled (Table 1).
The study included only children aged #10 years,because the goal of our study was to evaluate the phar-
macokinetics of micafungin in young children, espe-
cially as in prior pediatric studies, the rate of
clearance of micafungin increases at the ages of 8 years
and under. The median age was 3.9 years (range: 0.6-
10 years), and the male-to-female ratio was 11:4.
None of the patients had a history of previous fungal
infection.
The study design was approved by the Cincinnati
Children’s Hospital Medical Center’s institutional
review board (IRB), and consent was obtained from
each child’s parents before the child was enrolled in
the study. A separate Investigational New Drug
(IND) was also obtained from the Food and Drug
Administration (FDA).
Micafungin (Micamine) (Astellas Pharma US,
Inc., Deerfield, IL, USA) is a sterile, lyophilized prod-
uct for i.v. infusion that contains micafungin sodium.
The drug was reconstituted according to the manufac-
turer’s instructions to give approximately 10 mg mica-
fungin/mL solution. For infusion, this was added to
100 mL of 0.9% sodium chloride, and the final con-
centration for infusion was kept between 0.5 and 1.5
mg/mL. The diluted solution was protected from
light. All patients received a single dose of micafungin
(3 mg/kg) i.v. over 1 hour. Dose selection was based on
published PK data in pediatric patients [17], and
exploration of different dosing regimens using Monte
Carlo PK/PD simulation (SimLab, Monte Carlo anal-
ysis tool, Medimatics, Maastricht, The Netherlands).
Based on our simulation results, it was estimated that
a 3 mg/kg dose administered every 48 hours will likely
result in a similar micafungin trough concentration as
the currently used 1 mg/kg every 24 hours.PK Sampling
Serial blood samples were drawn around the single
dose of micafungin. Venous blood samples (2.0 mL)
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ately before the micafungin infusion (ie, time 5 0)
and then at 1 hour (ie, at the end of the infusion),
1.5, 2, 4, 6, 8, 10, 24, 36, and 48 hours after the start
of the micafungin infusion. In accordance with stan-
dard practice, all specimens were drawn from the
lumen where the micafungin was not infused.
Micafungin Assay
The concentration ofmicafungin in plasmawas de-
termined by a modified validated high-performance
liquid chromatography (HPLC) assay [17] in the Fun-
gus Testing Laboratory, Antifungal Levels Lab,
Department of Pathology, University of Texas Health
Science Center, San Antonio, Texas. The lower limit
of detection for this assay was 0.05 mg/mL. The
intraday coefficients of variation (CV) ranged from
1.28% to 9.87%. Interday CV for controls 0.5, 7.5,
and 18.75 mg/m$ were 8.10%, 5.44%, and 5.58%,
respectively.
PK Analysis
PK analyses of data were conducted using standard
noncompartmental methods (WinNonlin Professional
version 5.2.1; Pharsight, Mountain View, CA, USA).
Individual plasma trough concentrations were deter-
mined using the 48-hour plasma concentration data.
The apparent terminal elimination rate constant (lz)
for micafungin was estimated for each subject by non-
linear regression analysis. The area under the plasma
concentration-time curve (AUC0-t; AUC0-INF) was
determined using the log linear trapezoidal method.
Total body clearance (CL), volume of distribution at
steady state (Vss), and terminal half-life (T
1⁄2 ) were
calculated using standard equations.
Statistical Analysis
Data are presented as mean 6 standard deviation
(SD). A P value\ .05 was considered significant. Asso-
ciations between pharmacokinetic measures and pa-
tient data (eg, age, height [Ht], body weight [Wt],
body surface area [BSA], body mass index) were evalu-
ated using Spearman’s correlation coefficient at the
0.05 significance level. Statistical analyses were per-
formed using SPSS version 11.5 for Windows (SPSS,
Chicago, IL, USA).0 12 24 36 48
0
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Figure 1. Mean concentration-time profiles of micafungin (3 mg/kg
dose) in pediatric HSCT patients (mean data points 6 SD).RESULTS
All 15 patients completed the PK study. Micafun-
gin at a 3 mg/kg dose was well tolerated in all patients.
The Common Terminology Criteria for Adverse
Events (CTCAE) version 3.0 was used to evaluate
adverse events. One patient developed nonspecific ab-
dominal pain on day 1 that resolved without therapy
(grade 1). Two patients had mild hypocalcemia, and1 patient developed mild hypocalcemia, hypokalemia,
and had low albumin (all grade 1). The mean serum
creatinine level was similar to the pretreatment level
when measured at 48 hours. Mean liver function tests
at the end of study were similar to the starting levels,
except in 2 patients, who hadmodestly elevated alanine
aminoaspartate (from 36 to 93, and 39 to 114) and
alanine aminotransferase levels (from 18 to 49, and 9
to 71), and 1 of these also developed elevated GGT
(all grade 1). Additionally, 1 patient each had increase
in alanine aminoaspartate, alanine aminotransferase,
and GGT level (grade 1 again).
The mean concentration-time profiles of micafun-
gin in plasma after single dose are shown in Figure 1.
Peak concentrations observed at the end of the mica-
fungin infusion ranged from 8.3 to 18.7 mg/L. The
elimination half-life ranged from 9.5 to 16.8 hours,
comparable to previous pediatric PK data [17]. PK
parameter estimates after a single dose (3 mg/kg) of
micafungin for all 15 patients are summarized in
Table 2. Measurable plasma concentrations were
present in all cases at 48 hours (Figure 1 and Table 2).
Clearance was comparable to previous pediatric
PK data [17], but was higher than adults, as expected.
Volume of distribution was higher in our patients
compared to published pediatric data, likely because
of a larger proportion of very young children in our
study cohort (\2 years, n 5 3; 2-5 years, n 5 9; 5-10
years, n 5 3), and correlated well with body weight
(R2 5 0.76). Body weight explained 30% of the
variability observed in the estimates for micafungin
clearance (R2 5 0.30).DISCUSSION
In this study we evaluated the PK of 3 mg/kg mica-
fungin for 48 hours after a single dose given to young
children (age #10 years). Our interest in alternate day
administration of micafungin came from a couple of
sources. Administering long-term oral antifungal
Table 2. Mean (SD) Pharmacokinetic Parameter Estimates
after Single-Dose Micafungin in 15 Patients
Parameters (Unit) Mean SD Range
Cmax (mg/L) 12.5 2.7 8.3-18.7
Cmin (mg/L at 48 hours) 0.8 0.5 0.3-2.0
AUC0-24 (h*mg/L) 128.5 35.9 79.3-229.2
AUC0-48 (h*mg/L) 164.4 50.7 97.5-305.2
AUC0-INF (h*mg/L) 180.8 62.2 104.2-352.9
CL (mL/h/kg) 17.7 5.8 7.9-29.6
T1⁄2 (h) 13.0 2.1 9.5-16.8
Vss (L/kg) 0.3 0.1 0.2-0.5
Cmax indicates peak plasma concentration; Cmin, trough plasma concen-
tration; AUC0-24, 0-48 and 0-INF, area under the plasma concentration-
time curve extrapolated from 0 to 24 hours, 0 to 48 hours, or or 0 to
infinity; T1⁄2 , elimination half-life; CL, total body clearance; Vss, volume
of distribution at steady state.
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challenging and unreliable. In addition, hepatic toxic-
ity is common, and may require dose interruption,
for example, in a recent meta-analysis of tolerability
and hepatotoxicity of different antifungals, 19.7% vor-
iconazole users and 17.4% of itraconazole users had el-
evated serum liver enzyme levels in comparision to 9%
for fluconazole and 3% for Micafungin users [21].
Long-term therapy with amphotericin B is associated
with renal toxicity. In the setting of pediatric HSCT,
it is not uncommon to have patients with both hepatic
and renal insufficiency, making echinocandins a partic-
ularly appropriate option for prophylaxis. Currently,
echinocandins require daily i.v. administration. The
second impetus for the study was that both animal
[22] and adult human data [23] have suggested that
alternate day dosing schedule may be effective, and
support the use of this schedule.
Our data show measurable plasma levels at 48
hours after a single 3 mg/kg dose of micafungin. It is
clearly important to consider whether the levels
achieved are likely to have meaningful antifungal activ-
ity. Previous in vitro time-kill studies with micafungin
have demonstrated fungicidal activity for mostCandida
strains. A postantifungal effect has also been shown,
and may be enhanced with higher drug concentrations
[24]. In addition, serum drug concentrations are used
in general as a relatively good surrogate of tissue con-
centrations. In 1 study of 2000 Candida bloodstream
isolates, most species (C. albicans, C. glabrata, C. tropi-
calis, and C. dubliniensis) exhibited minimum inhibitory
concentrations (MICs) of 0.03 to 0.06 mg/mL. The
MICs for C. krusei and C. lustitaniae were slightly
higher (0.6-2.0 mg/mL), with C. parapsilosis having
the highest MIC (1-2 mg/mL) [25]. The Clinical and
Laboratory Standards Institute (CLSI) has recently
established susceptibility breakpoints for echinocan-
dins against Candida spp. A MIC #2 mg/mL for all 3
echinocandin agents is classified as susceptible, and
a value $2 mg/mL is considered nonsusceptible [26].
Micafungin also has potent in vitro activity against As-
pergillus spp., including A. fumigatus,A. flavus,A. niger,A. versicolor, A terreus, and A. nidulans. MIC ranges of
0.0078-0.0156 mg/mL have been reported against
these Aspergillus spp.; however, standard susceptibility
breakpoints for the echinocandins against molds have
not been established. The minimum effective concen-
tration (MEC), which is the minimum concentration
noted to produce short and aberrant hyphal branching
under the microscope, has been proposed as an alter-
native measure, and has been reported as #0.125 mg/
mL for several Aspergillus spp., including A. fumigatus,
A. flavus, and A. niger [27]. These results were
confirmed in a recent study from Japan, which evalu-
ated in vitro antifungal activity of micafungin com-
pared to caspofungin, fluconazole, itraconazole,
voriconazole, and amphotericin B. Ninety-three Can-
dida and 23 Aspergillus isolates recovered from pediat-
ric patients with fungal infections were evaluated.
Micafungin showed potent activity against Candida
albicans, Candida tropicalis, and Candida glabrata,
with anMIC range of#0.002 to 0.015 mg/mL. In con-
trast, micafungin demonstrated higher MIC levels
against Candida parapsilosis with an MIC range of
0.12 to 2 mg/mL. Micafungin showed potent antifun-
gal activity against Aspergillus species tested with an
MIC range of 0.004 to 0.015 mg/mL [28].
Themean concentration of micafungin at 48 hours
(the end of interval in this study) was 0.8 mg/mL
(range: 0.3-2.0 mg/mL), which appears favorable con-
sidering the MIC distributions of most common
strains (Candida , #0.06 mg/mL; Aspergillus, # 0.016
mg/mL). However, after correction for the high pro-
tein binding (99%), free micafungin concentrations
at the end of the dosing interval only exceeds the
MIC of highly susceptible fungal pathogens. The im-
plications of this observation and the potential contri-
bution of postantifungal effects (ie, ongoing antifungal
activity at concentrations below the MIC) will be ex-
plored in a future Monte Carlo Simulation PK/PD
study using epidemiologic fungal MIC distribution
data for common fungal pathogens, with the goal of
finding the regimen that would provide adequate
coverage based on the pharmacodynamic index param-
eters (eg, AUC/MIC ratio) [29]. Gumbo et al. [22]
have demonstrated prolonged antifungal effects of
micafungin in neutropenic mice with disseminated C.
glabrata. This animal study showed that micafungin
has a true in vivo postantifungal effect, which for doses
of 3 mg/kg in mice (serum AUC0-INF 5 64 mg*h/L)
lasted for around 5 days after decline of tissue concen-
trations below the C. glabrata MIC. Moreover, when
the whole 10-day cumulative dose (30 mg/kg) was ad-
ministered, micafungin’s effect lasted for up to 7 days.
Our data, suggesting that alternate day dosing is an
effective strategy are in agreement with a study in
adults, published in abstract form in 2005. A multicen-
ter, multinational, double blind, noninferiority trial of
adult patients with esophageal candidiasis, evaluated
1462 Biol Blood Marrow Transplant 16:1458-1462, 2010P. A. Mehta et al.every other day dosing of micafungin (300 mg every
other day) versus daily micafungin (150 mg) versus
daily dosing of caspofungin. This study concluded
that every other day dosing of micafungin was a safe
and effective alternative to daily dosing of micafungin
or caspofungin [23].
Our PK data, along with the fact that 3 mg/kg dos-
ing was well tolerated, with no infusion toxicity and no
renal, major hepatic, or other toxicities, suggests that
alternate day micafungin dosing, as described here,
may provide an attractive alternative for antifungal
prophylaxis in HSCT patients. Although our study
was not designed to prove the efficacy of this approach,
the data provide support for a prospective clinical
study of this prophylaxis strategy as a safe strategy
for long-term use.
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